Inhibikase Therapeutics, Inc. (IKT) Return on equity 2020–2024
Inhibikase Therapeutics, Inc. (IKT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-29.0%FY2024 · since FY2020: -29.1% → -29.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -29.0% | +144.3 pp |
| FY2023 | -173.3% | -87.5 pp |
| FY2022 | -85.8% | -47.3 pp |
| FY2021 | -38.5% | -9.4 pp |
| FY2020 | -29.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice